U.S. and Japanese authorities have approved filings for Bristol Myers Squibb's Breyanzi, aimed at treating recurrent Follicular and Mantle Cell Lymphomas.

Vertex Reveals Encouraging Outcomes from Phase 3 Trials of VX-548 for Moderate to Intense Short-Term Pain Management.

CellVax Therapeutics has received approval from the FDA for its IND submission for FK-PC101, a new individualized immunotherapy treatment for cancer.

DP Tech has revealed its selection of a developmental contender, a promising top-tier Kv1.3 blocker aimed at tackling immune disorders like IBD and AD.

EicOsis Human Health has announced the advancement of its clinical research program, beginning a Phase 1b trial to assess the safety of its experimental drug, EC5026, through increasing dosages.

EMA evaluates GSK's Arexvy, an RSV immunization, for approval to protect adults 50-59 with high risk from RSV infection.

GSK plc announced the European Commission's approval of Omjjara (momelotinib) for market launch. This daily oral drug inhibits both JAK1/JAK2 and activin A receptor type 1.

Alvotech Reveals Encouraging Preliminary Findings from Drug Behavior Analysis of AVT03, a Potential Equivalent to Prolia® and Xgeva®.

Oricell has received the green light from the FDA for its investigational new drug (IND) application for OriCAR-017, an innovative CAR-T therapy aimed at GPRC5D.

Sarepta Therapeutics Reveals Encouraging Results from Segment B in the MOMENTUM Phase 2 Trial for SRP-5051, Targeting Exon 51 Skip-Amenable Duchenne Muscular Dystrophy Cases.

Takeda has disclosed that GAMMAGARD LIQUID®, their intravenous immunoglobulin treatment, has received authorization from the U.S. Food and Drug Administration.

Alligator Bioscience Reveals Encouraging Phase 2 Outcomes from OPTIMIZE-1 Study, Succeeding in Main Goal and Showing Significant Survival Advantages for Initial Treatment of Pancreatic Cancer.